b013
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 6, 2022 (NCT05555706)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06434610 | Phase 2 | Jul 11, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05555706 | Phase 2/Phase 3 (Phase 3) | Dec 6, 2022 | Peking University, Shanghai Pharmaceuticals Holding Co., Ltd, Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 2 | 2 | 2 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1